Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion
I'm PortAI, I can summarize articles.
Pharmaron Beijing Co., Ltd. has raised approximately HK$1.32 billion through the placement of 58,440,762 new H shares at HK$22.82 per share. The funds will be used for expanding project development, increasing laboratory services and drug manufacturing capabilities, and for debt repayment. Following this transaction, the proportion of H shares increased from 16.62% to 19.28%, slightly diluting existing holdings. The company's market cap is HK$56.88 billion, with a current analyst rating of Hold and a price target of HK$24.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments